Poseida Therapeutics (NASDAQ:PSTX) Earns “Buy” Rating from HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $20.00 price target on the stock.

Poseida Therapeutics Trading Up 2.2 %

NASDAQ:PSTX traded up $0.06 during midday trading on Thursday, reaching $2.83. 833,059 shares of the stock traded hands, compared to its average volume of 716,364. The company has a fifty day moving average of $2.97 and a 200 day moving average of $2.94. Poseida Therapeutics has a 12 month low of $1.54 and a 12 month high of $4.27. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.18 and a current ratio of 3.18. The stock has a market capitalization of $274.31 million, a P/E ratio of -2.04 and a beta of 0.46.

Poseida Therapeutics (NASDAQ:PSTX) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 190.76% and a negative return on equity of 94.90%. The company had revenue of $25.00 million during the quarter, compared to analyst estimates of $12.50 million. On average, research analysts predict that Poseida Therapeutics will post -1.77 EPS for the current year.

Institutional Trading of Poseida Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio purchased a new stake in Poseida Therapeutics during the 4th quarter valued at about $76,000. Cantor Fitzgerald L. P. purchased a new stake in Poseida Therapeutics during the 4th quarter valued at about $169,000. Tower Research Capital LLC TRC boosted its holdings in shares of Poseida Therapeutics by 110.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock valued at $36,000 after acquiring an additional 5,606 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Poseida Therapeutics during the 4th quarter valued at about $36,000. Finally, MCF Advisors LLC boosted its holdings in shares of Poseida Therapeutics by 476.4% during the 4th quarter. MCF Advisors LLC now owns 247,024 shares of the company’s stock valued at $830,000 after acquiring an additional 204,170 shares during the last quarter. 46.87% of the stock is owned by hedge funds and other institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.